Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. It has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018 Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable
Depomed (NYSE:ASRT) Frequently Asked Questions
What is Depomed's stock symbol?
Depomed trades on the New York Stock Exchange (NYSE) under the ticker symbol "ASRT."
How were Depomed's earnings last quarter?
Depomed, Inc. (NYSE:ASRT) released its quarterly earnings data on Wednesday, November, 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.26. The business earned $55.15 million during the quarter, compared to the consensus estimate of $59.26 million. View Depomed's Earnings History.
When is Depomed's next earnings date?
What price target have analysts set for ASRT?
1 analysts have issued 12-month price objectives for Depomed's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Depomed's stock price to reach $3.00 in the next year. This suggests a possible upside of 291.3% from the stock's current price. View Analyst Price Targets for Depomed.
What is the consensus analysts' recommendation for Depomed?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Depomed in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Depomed.
Has Depomed been receiving favorable news coverage?
Headlines about ASRT stock have trended positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Depomed earned a coverage optimism score of 2.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Depomed.
Who are some of Depomed's key competitors?
Some companies that are related to Depomed include Green Organic Dutchman (TGOD), ICC Labs (ICC), Supreme Cannabis (FIRE), Shield Therapeutics (STX), CannTrust (TRST), Amryt Pharma (AMYT), Probiotec (PBP), ESSA Pharma (EPI), Auscann Group (AC8), WeedMD (WMD), Biosyent (RX), Delta 9 Cannabis (NINE), Althea Group (AGH), cbdMD (YCBD) and Invion (IVX).
What other stocks do shareholders of Depomed own?
Who are Depomed's key executives?
Depomed's management team includes the folowing people:
- Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
- Mr. Phillip B. Donenberg, CFO & Sr. VP (Age 57)
- Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
- Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)
- Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54)
Who are Depomed's major shareholders?
Depomed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Public Employees Retirement System of Ohio (0.11%). Company insiders that own Depomed stock include Arthur J Higgins, Daniel A Peisert, Karen A Dawes, Peter D Staple, Stan Bukofzer and William Mckee. View Institutional Ownership Trends for Depomed.
Which major investors are selling Depomed stock?
ASRT stock was sold by a variety of institutional investors in the last quarter, including Public Employees Retirement System of Ohio. Company insiders that have sold Depomed company stock in the last year include Karen A Dawes and William Mckee. View Insider Buying and Selling for Depomed.
How do I buy shares of Depomed?
Shares of ASRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Depomed's stock price today?
One share of ASRT stock can currently be purchased for approximately $0.77.
How big of a company is Depomed?
What is Depomed's official website?
MarketBeat Community Rating for Depomed (NYSE ASRT)
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe ASRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASRT will underperform the S&P 500 over the long term. You may vote once every thirty days.
